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Abstract
Background: The mannose 6-phosphate/insulin-like growth factor-II receptor (M6P/IGF2R) is a
multi-functional protein that has been implicated in regulation of cell growth and apoptosis. Cardiac
myocytes express relatively high levels of M6P/IGF2R, and cardiomyocyte apoptosis has been
identified in a variety of cardiovascular disorders, such as myocardial infarction and heart failure.
However, involvement of M6P/IGF2R in the pathogenesis of these conditions has not been
determined. Thus, the objective of this study was to determine the role of M6P/IGF2R in regulation
of cardiac myocyte growth and apoptosis.
Results: We down-regulated the expression of M6P/IGF2R in neonatal rat cardiac myocytes and
examined the effect on cell proliferation and apoptosis. Infection of neonatal cardiomyocytes with
an adenovirus expressing a ribozyme targeted against the M6P/IGF2R significantly reduced the level
of M6P/IGF2R mRNA, as determined by RT-PCR and Ribonuclease Protection Assay (RPA). M6P-
containing protein binding and endocytosis as well as the M6P/IGF2R-mediated internalization of
125I-IGF-II were lower in the ribozyme-treated cells than the control myocytes, indicating that the
number of functional M6P/IGF2R in the ribozyme treated cells was reduced. Accordingly, a marked
increase in cell proliferation and a reduced cell susceptibility to hypoxia- and TNF-induced
apoptosis were observed in the ribozyme-treated cells.
Conclusions: These findings suggest that M6P/IGF2R may play a role in regulation of cardiac
myocyte growth and apoptosis. Down regulation of this gene in cardiac tissues might be a new
approach to prevention of cell death or promotion of mitogenesis for certain heart diseases.
Background
The mannose 6-phosphate/insulin-like growth factor-II
receptor (M6P/IGF2R) is a unique protein that interacts
with multiple ligands, some of which are important
growth regulatory factors [1]. The M6P/IGF2R participates
in internalization and lysosomal degradation of IGF-II, a
mitogen normally acting through the IGF-I receptor to
stimulate cell proliferation [2]. The M6P/IGF2 receptor is
required for the activation of TGF-β [3], a potent growth
inhibitor for many cell types. This receptor is also
involved in the binding, transport and activation of
newly-synthesized lysosomal enzymes, such as cathepsins
[4,5], which have been recently implicated in the induc-
tion of apoptosis [6]. On the basis of these functions, the
M6P/IGF2R has been proposed to play a significant role
in regulation of cell growth and apoptosis [7].
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Apoptosis, or programmed cell death, is a tightly regu-
lated process used to remove excess, hazardous or dam-
aged somatic cells, and is crucial for the development,
maintenance and survival of an organism. However, alter-
ations in the control of apoptosis have also been shown to
contribute to human diseases. In fact, morphological and
biochemical markers of apoptosis have been identified in
a wide variety of cardiovascular disorders, including myo-
cardial infarction and heart failure. This suggests that acti-
vation of apoptotic pathways contributes to
cardiomyocyte loss and subsequent cardiac dysfunction
in these conditions. A number of factors involved in car-
diomyocyte apoptosis are currently known and include
insulin-like growth factor-I (IGF-I), stress-activated pro-
tein kinases (SAPKs) and the anti-apoptotic Bcl-2 family
[8]. There are indications that other factors may be
involved in induction and regulation of cardiac apoptosis.
However, these potential factors and their corresponding
mechanisms have not been identified.
Several lines of evidence point to the potential involve-
ment of M6P/IGF2R in cardiac myocyte proliferation and
apoptosis. Cardiac myocytes express relatively high levels
of M6P/IGF2R and transgenic mice containing a homolo-
gous deletion of the M6P/IGF2R gene manifest ventricular
hyperplasia due to an increase in cell number [9,10], sug-
gesting that the M6P/IGF2R normally acts to suppress car-
diac myocyte cell growth. It has also been shown that
TGF-β, a potent growth suppressor whose activation
requires the binding of latent TGF-β to M6P/IGF2R [3], is
commonly upregulated in chronic heart failure [11].
Additional evidence for the involvement of M6P/IGF2R in
regulation of apoptosis comes from studies of tumorigen-
esis. It has been shown that M6P/IGF2R expression is sig-
nificantly reduced in a variety of tumors and loss of
heterozygocity (LOH) at the M6P/IGF2R gene locus 6q26
have been found in breast, liver cancers and squamous
cell carcinoma of the lung [12-15]. Although several stud-
ies have examined the effect of M6P/IGF2R over-expres-
sion on cell growth [7], it is not known whether down-
regulation of this receptor protein leads to cellular protec-
tion against apoptosis.
Ribozymes are catalytic RNA molecules that cleave a com-
plementary mRNA sequence [16], thereby inactivating
specific mRNAs and suppressing gene expression in vitro
and in vivo [17,18]. Ribozymes have been shown to be
highly specific, efficient and stable. They can be packaged
into viral vectors to enhance transfer into cells and to
achieve longer expression compared with naked oligonu-
cleotides. In the present study, we employed ribozyme
technology to study the role of M6P/IGF2R in regulation
of cardiac myocyte cell growth. A hammerhead ribozyme
against the M6P/IGF2R mRNA was constructed and pack-
aged in an adenoviral vector. We then examined the effect
of ribozyme-mediated down-regulation of M6P/IGF2R
expression on cell growth and hypoxia- and TNF-induced
apoptosis.
Results
Cleavage reaction of the ribozyme in vitro
The M6P/IGF2R ribozyme we constructed has 13-bp
binding arms complementary to the target site of M6P/
IGF2R mRNA, and a catalytic core (Fig. 1A). To evaluate
the bioactivity of the ribozyme and the accessibility of the
target site, a cleavage reaction was performed in vitro. The
substrates, [α-32P] labeled RNA transcripts containing 45
bp of M6P/IGF2R mRNA or an unmatched sequence,
were incubated with the ribozyme as described (see Mate-
rials and Methods). The ribozyme cleaved only the spe-
cific M6P/IGF2R mRNA into the expected products. In the
assay of time course, the hammerhead ribozyme was able
to cleave 24.2% of the M6P/IGF2R target within 10 min-
utes of incubation, 50.3% of the M6P/IGF2R target within
40 minutes of incubation, and by 640 minutes, 80.8% of
the M6P/IGF2R target was converted to the expected prod-
ucts (Fig. 1B). This ribozyme did not digest the
unmatched sequence (Fig. 1B). These results indicate a
high efficiency and specificity of the ribozyme in vitro.
Ribozymes down-regulate M6P/IGF2R expression in 
cardiac myocytes
To examine the ability of the ribozyme to reduce levels of
M6P/IGF2R mRNA in cultured cardiac myocytes, total
RNA was extracted from cells infected with Ad-GFP/
IGF2R-Rz or Ad-GFP, and subjected to RT-PCR using
M6P/IGF2R-specific primers. Primers specific for β-actin
were added to a parallel reaction to serve as an internal
standard. Cells were used 4 days after infection, with aver-
age infection efficiency of 70–80% (for which a viral dose
used had minimal cytotoxicity). The RT-PCR product of
M6P/IGF2R was 856 bp, and the β-actin product was 285
bp. As shown in Fig. 2A, the Ad-GFP/IGF2R-Rz-infected
cells exhibited a significantly lower level of M6P/IGF2R
mRNA than Ad-GFP-infected cells, with a reduction of
about 50%. This result was confirmed by ribonuclease
protection assay (RPA), in which GAPDH was used as a
control (Fig. 2C &2D). There was no significant difference
in the level of M6P/IGF2R mRNA between Ad-GFP-
infected cells and uninfected cells (data not shown), indi-
cating that infection with the adenovirus itself did not
alter the endogenous M6P/IGF2R mRNA level. The results
demonstrated that the ribozyme was highly effective in
suppressing M6P/IGF2R expression in cultured cardiac
myocytes.
Effect of ribozyme expression on the functional activity of 
M6P/IGF2R
To determine the effect of the ribozyme on the functional
activity of M6P/IGF2R, binding and internalization ofBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/15
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exogenous 125I-IGF-II was measured in cells infected with
Ad-GFP/IGF2R-Rz. As shown in Fig. 3A, cells infected with
Ad-GFP/IGF2R-Rz showed a 54% reduction in 125I-IGF-II
internalization when compared with the control cells
(infected with Ad-GFP). We also examined the effect of
the ribozyme on the M6P-binding activity of the M6P/
IGF2R using the M6P-bearing lysosomal enzyme, β-glu-
curonidase, as a probe. The results showed that the maxi-
mal M6P-binding capacity of cells treated with the
ribozyme was about 50% less than that of controls (Fig.
3B). Furthermore, we assessed the ability of cells to inter-
nalize exogenous β-glucuronidase after treatment with
ribozyme. Similarly, the M6P-inhibitable endocytosis of
β-glucuronidase by ribozyme-treated cells was about 52%
less than that of control cells (Fig. 3C). These results con-
firm that the number of functional M6P/IGF2R in
ribozyme-treated cells was reduced.
Adenoviral delivery of ribozymes increases the 
proliferation of cardiac myocytes
We examined the effects of the ribozyme on the growth of
cultured neonatal rat cardiac myocytes. Morphological
evaluation showed a remarkable difference in growth pat-
tern between Ad-GFP/IGF2R-Rz-infected cells and the
control cells: the ribozyme-expressing cells formed larger
and more spread colonies (Fig. 4). Assessment of cell pro-
liferative activity by the MTT assay and counts of viable
cells showed that the number of cardiac myocytes in
ribozyme-expressing cultures was significantly higher
than in control cultures (Fig. 5). These results indicate that
treatment with M6P/IGF2R-ribozyme can promote car-
diac myocyte proliferation.
Effect of M6P/IGF2R-ribozyme expression on apoptosis of 
cardiac myocytes
We examined the effects of ribozyme expression on TNF-
α and hypoxia-induced apoptosis of cultured cardiac
myocytes. After a 24 hr challenge with hypoxia, the
number of apoptotic cells in M6P/IGF2R-Rz expressing
cultures was 38% lower than in control cultures as deter-
mined by Hoechst staining (which highlights the nuclei of
apoptotic cells) and ELISA (Fig. 6A, 7A). MTT analysis
showed that the number of viable cells in ribozyme-
treated cultures was 40% higher than in control cultures
(Fig. 7A).
After treatment with TNF-α, as shown in Fig. 6B, a large
number of control cells underwent apoptosis, as indicated
by morphological changes (small round shape) and
bright blue nuclear staining. There were significantly more
apoptotic cells in control cultures than in cultures express-
ing the Ad-GFP/IGF2R-Rz. The number of apoptotic cells,
as measured by the cell death ELISA assay, in cultures
infected with Ad-GFP/IGF2R-Rz was significantly (about
40%) lower than in cultures infected with Ad-GFP (Fig.
7B). Accordingly, the number of viable cells, as measured
by MTT analysis, in cultures infected with Ad-GFP/IGF2R-
Rz was significantly (about 45%) higher than in cultures
infected with Ad-GFP (Fig. 7B). These results are consist-
ent with the hypothesis that decreasing M6P/IGF2R
expression by ribozyme treatment can reduce cell
apoptosis.
Discussion
Some 62,000,000 Americans have one or more types of
cardiovascular disease (CVD) and CVD is the leading
cause (40.1%) of death in the United States. Myocardial
infarction and heart failure, conditions accompanied by
Hammerhead ribozyme structure and target sequence of the  M6P/IGF2R mRNA (A) and ribozyme activity against M6P/ IGF2R RNA in vitro (B) Figure 1
Hammerhead ribozyme structure and target sequence of the 
M6P/IGF2R mRNA (A) and ribozyme activity against M6P/
IGF2R RNA in vitro (B). 32P-labeled RNA containing the 
M6P/IGF2R target sequence was incubated with the hammer-
head ribozyme and the reaction products were separated by 
polyacrylamide gel. The ribozyme cleaves the M6P/IGF2R 
target efficiently and specifically in vitro. Lane 1: Specific target 
alone; Lane 2: Specific target incubation with ribozyme at 
time 0; Lane 3–10: Specific target incubation with ribozyme 
at a time-course of 5, 10, 20, 40, 80, 160, 320 and 640 min-
utes; Lane11: Unmatched target alone; Lane 12: Unmatched 
target incubation with ribozyme at 640 minutes.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/15
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Effect of the ribozyme on M6P/IGF2R mRNA in cardiac myocytes Figure 2
Effect of the ribozyme on M6P/IGF2R mRNA in cardiac myocytes. (A) A representative RT-PCR result showing the levels of 
M6P/IGF2R mRNA (lanes 1 and 2) and the corresponding amounts of β-actin mRNA (lanes 3 and 4) in the ribozyme-treated 
myocytes (lane 1, lane 3) and in the control cells (lane 2, lane 4). (B) Bar chart showing percent change in M6P/IGF2R mRNA 
of the ribozyme-treated cells relative to the mRNA fraction in the control cells (normalized to β-actin). The data are average ± 
SE of at least three independent experiments (*, P < 0.05 versus control). (C) RPA analysis of M6P/IGF2R down-regulation by 
ribozyme treatment (lane 1, ribozyme-treated; lane 2, control) (see methods for procedure). A probe targeting the GAPDH 
gene was used as an internal control. (D) Bar chart showing percent change in M6P/IGF2R mRNA of the ribozyme-treated 
cells relative to the mRNA fraction in the control cells (normalized to GAPDH). The data are average ± SE of at least four 
independent experiments (*, p < 0.05 versus control).BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/15
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cardiac myocyte apoptosis, represent 23% of all CVDs and
are a growing clinical challenge in need of novel therapeu-
tic strategies. In this study, we investigated the M6P/
IGF2R as a potential new therapeutic target for reduction
of cardiac apoptosis and cardiac injury in these
conditions.
Using ribozyme technology we down-regulated the
expression of the M6P/IGF2R in neonatal cardiac myo-
cytes. We then examined cell proliferation and apoptosis
under normal conditions and post challenge with either
hypoxia, a model of ischemia-reperfusion, or TNF-α, a
cytokine implicated in the pathogenesis of chronic heart
failure [19]. Our results demonstrate an association of a
decrease in the expression and function of the M6P/IGF2R
with increased cell proliferation and decreased cell suscep-
tibility to hypoxia- and TNF-induced apoptosis. Expres-
sion of the ribozyme targeted against the M6P/IGF2R in
cardiomyocytes resulted in down-regulation of M6P/
IGF2R expression, as measured by RT-PCR and RPA, and
of M6P/IGF2R function, as indicated by a decrease in
internalization of 125I-IGF-II, and β-glucuronidase bind-
ing and endocytosis.
MTT analysis and viable cell counts showed that
ribozyme-mediated down-regulation of M6P/IGF2R
resulted in a marked increase in cell proliferation of cardi-
omyocytes, which normally express high levels of M6P/
IGF2R [20] and have limited proliferative capabilities
[21]. These results are consistent with the findings of pre-
vious knockout studies [9,10]. Since the M6P/IGF2R has
multiple actions on cell growth, its proliferative effect on
the heart cells observed in this study might involve multi-
ple mechanisms. However, it is likely that unchecked IGF-
II stimulation plays a key role in the effect. Because the
M6P/IGF2R is believed to sequester and degrade IGF-II
[2], a decrease in M6P/IGF2R expression and function
could result in decreased degradation and hence increased
bioavailability of IGF-II to the IGF-I receptor, which medi-
ates the growth-promoting effect of IGF-II. Supporting
evidence for the involvement of IGF-II in the proliferative
effect resulting from loss of M6P/IGF2R function comes
from studies of M6P/IGF2R knock-out mice. M6P/IGF2R-
Effect of the ribozyme on the internalization of 125I-labeled IGF-II (A) Figure 3
Effect of the ribozyme on the internalization of 125I-labeled IGF-II (A). Ribozyme-treated or control cells were incubated in 
serum-free F-10 culture medium containing 125I-labeled IGF-II with or without excess unlabeled IGF-II. Following the incuba-
tion, cell-associated radioactivity was determined by a γ counter. Determination of binding (B) and endocytosis (C) of M6P-
containing protein in cells. The M6P/bearing enzyme β-glucuronidase was used as a probe. The M6P-inhibitable binding was 
measured by incubating saponin-peameabilized cells with β-glucuronidase in the presence or absence of M6P. The M6P-inhib-
itable uptake was determined by incubating cells with medium containing β-glucuronidase in the presence or absence of M6P. 
Following incubation, cells were washed extensively, and cell-associated β-glucuronidase was measured fluorometrically. The 
data are average ± SE of at least four independent experiments (*, p < 0.05 versus control).BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/15
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null mice display global hyperplasia that coincides with
elevated levels of IGF-II. Most importantly, however, the
lethal nature of an M6P/IGF2R-null phenotype is reversed
in an IGF-II-null background [9]. Our results showing that
ribozyme-mediated down-regulation of M6P/IGF2R lead
to a decrease in IGF-II internalization support the above
possibility. However, further investigation to confirm this
mechanism is warranted.
More importantly, our results also showed that M6P/
IGF2R down-regulation resulted in decreased sensitivity
of cardiomyocytes to hypoxia- and TNF-induced
apoptosis. There is evidence that lysosomal enzymes, such
as cathepsins B and D contribute to hypoxia- and TNF-
induced apoptosis in vitro [22-25] and in vivo [26,27]. The
M6P/IGF2R has been shown to be involved in binding,
transport and activation of lysosomal enzymes, including
cathepsins [4,5]. Therefore, it is possible that down-regu-
lation of the M6P/IGF2R results in improper trafficking
and activation of cathepsins. This, in turn would elimi-
nate the apoptotic cascades triggered by these enzymes
under hypoxia and TNF stimulation and result in
decreased sensitivity of cardiomyocytes to apoptosis.
It has also been shown that TNF stimulation involves the
activation of TGF-β [28-30], a ligand of M6P/IGF2R that
Microphotographs showing the effect of the ribozyme on the growth of neonatal rat cardiac myocytes Figure 4
Microphotographs showing the effect of the ribozyme on the growth of neonatal rat cardiac myocytes. Cells were infected 
with Ad-GFP/IGF2R-Rz or Ad-GFP. The photographs were taken directly from the culture plate under 510 nm light (upper 
panels) and under bright light (lower panels) using a fluorescence microscope.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/15
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has been implicated in the progression of chronic heart
failure [11,31]. Therefore, down-regulation of M6P/
IGF2R expression could also lead to a decreased bioavail-
ability of activated TGF-β, thereby decreasing the sensitiv-
ity of cardiomyocytes to the TNF/TGF-β apoptotic
pathway. The detailed mechanism of the observed effects
is unknown and requires further investigation.
Conclusions
The present study demonstrates that ribozyme-mediated
down-regulation of expression and functional activity of
the M6P/IGF2R results in a decrease in the susceptibility
of cardiac myocytes to apoptotic stimuli. These findings
suggest that this receptor might be involved in cardiac cell
growth and apoptosis. The ability of the M6P/IGF2R
ribozyme to reduce M6P/IGF2R expression and function
in transfected cells verifies the utility of the ribozyme in
studying the role of M6P/IGF2R in cardiomyocyte growth
and apoptosis. In addition to its utility as a research tool,
the ribozyme, with further exploration and development,
might have potential application as a therapeutic agent to
prevent cell death or promote mitogenesis for certain clin-
ical conditions, such as, myocardial infarction and
chronic heart failure.
Methods
Construction of recombinant M6P/IGF2R-RZ adenoviral 
vector
The nucleotide numbers of the rat M6P/IGF2R sequence
targeted by the hammerhead ribozyme is 1147–1160 after
coding site (exon 9). The structure of the M6P/IGF2R
hammerhead ribozyme is shown in Fig. 1. A 49 bp M6P/
IGF2R ribozyme oligonucleotide, 5'-GAATTCCCC
ACACTG ATGAGCCGCTTCGGCGGCGAAACATTCAAC
GCGT-3' and the corresponding reverse complementary
strand were synthesized. The fragments were subcloned to
Effects of the ribozyme on proliferation of cardiac myocytes Figure 5
Effects of the ribozyme on proliferation of cardiac myocytes. Cells were infected with Ad-GFP/IGF2R-Rz or Ad-GFP, and then 
analyzed by MTT assay (A) and by cell counts (B). The data are average ± SE of at least four independent experiments (*, p < 
0.05 versus control).BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/15
Page 8 of 12
(page number not for citation purposes)
produce a plasmid containing a ribozyme against M6P/
IGF2R. For construction of the recombinant adenovirus
containing the M6P/IGF2R-ribozyme (pAd-GFP/IGF2R-
Rz), the segments containing the ribozymes were ampli-
fied by PCR and cloned into a pAdTrack-CMV vector and
then recombined homologously with an adenoviral
backbone pAdEasy 1 vector to generate (pAd-GFP/IGF2R-
Rz), following the protocol described by He et al. [32].
The pAd-GFP/IGF2R-Rz carries both the IGF2R-Rz and
GFP (as reporter) genes, each under the control of sepa-
rate cytomegalovirus (CMV) promoters. Another viral vec-
tor, pAd-GFP, which carries the GFP gene only under the
control of the CMV promoter, was generated and used as
a control vector. The adenoviral vector DNA were liner-
ized with Pac I and transfected into the replication-per-
missive 293 cells (E1A transcomplementing cell line) by
using Lipofectamine (Life Technologies) to produce E1-
deleted, replication-defective recombinant adenovirus as
described previously [33]. Large-scale amplification of
recombinant adenovirus in 293 cells was followed by
purification using a discontinuous CsCl gradient. The
constructs were confirmed by enzymatic digestion and
DNA sequencing.
Transcription and cleavage reaction of ribozyme in vitro
Plasmids containing the ribozyme or the substrate (either
45 bp of M6P/IGF2R mRNA or an unmatched sequence
5'-GTGCTGTCTGTATG-3') were linearized with MluI,
respectively. All transcripts were generated with T7 RNA
polymerase (Promega). Substrate transcripts were labeled
by incorporation of [α-32P] UTP (NEN Life Science Prod-
ucts, Inc.). Specific activity of the [α-32P] UTP (10 µCi/µl)
and the base composition of each substrate molecule were
used to calculate the substrate concentration. Ribozyme
transcripts were quantified spectrophotometrically. (The
half-life of the M6P/IGF2R target is about 280 minutes).
Cleavage reaction mixture contained substrate RNA (40
nM), increasing amounts of ribozyme (60 nM), 20 mM
MgCl2 and 20 mM Tris-HCl, pH8.0, in a final volume of
10 µl. The mixture was incubated at 37°C for a time-
course of cleavage reaction from 0, 5, 10, 20, 40, 80, 160,
320, to 640 minutes and the cleavage reaction was
stopped by addition of loading buffer (80% formamide,
10 mM Na2EDTA, pH 8.0, and 1 mg/ml each bromophe-
nol blue and xylene cyanol). Cleavage products were ana-
lyzed on a 15% polyacrylamide and 8M urea gel. Product
and substrate fragments were quantitated by using NIH
Imager.
Cell cultures and infection with Ad-GFP/Rz-IGF2R and Ad-
GFP
Cardiac myocytes were isolated from 1-day-old newborn
rats using the Neonatal Cardiomyocyte Isolation System
(Worthington). The isolated cells were plated in 6-well
plates and cultured in F-10 medium containing 5% (vol/
vol) FBS and 10% (vol/vol) horse serum at 37°C in a tis-
sue culture incubator with 5% CO2 and 98% relative
humidity. Cells were used for experiments after 2–3 days
of culture. Viral infections were carried out by adding viral
particles at various concentrations (usually, 2 × 108 virus
particles/ml) to culture medium containing 2% (vol/vol)
FBS. Initially, optimal viral concentration was determined
by using Ad-GFP to achieve an optimal balance of high
gene expression and low viral titer to minimize cytotoxic-
ity. After 24 hours of incubation, the infection medium
was replaced with normal (15% vol/vol serum) culture
medium. For treatment with IGF-II, cells were incubated
with 50 ng/ml IGF-II after 24 hours infection with Ad-
GFP/IGF2R-Rz or Ad-GFP. Four days after infection, cells
were used for analysis of gene expression of M6P/IGF2R
and its effect on cell growth and apoptosis.
Analysis of gene expression in cardiac myocytes
The M6P/IGF2R transcripts were determined by both RT-
PCR and Ribonuclease Protection Assay (RPA). RT-PCR
Effects of the IGF2R ribozyme on the apoptosis induced by  hypoxia and TNF treatment in cardiac myocytes Figure 6
Effects of the IGF2R ribozyme on the apoptosis induced by 
hypoxia and TNF treatment in cardiac myocytes. Cells were 
infected with Ad-GFP (control) or Ad-GFP/IGF2R-Rz. 72 
hours post infection, cells were challenged with either 
hypoxia (A) or TNF (B) for one day and then cell death was 
examined using a fluorescence microscope. Cells were 
stained with Hoechst dye for nuclei and observed under 480 
nm blue-fluorescent light. The bright blue spots are the 
nuclei of apoptotic cells.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/15
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was performed using the GeneAmp EZ rTth RNA PCR kit
(Roche). Total RNA was extracted from cultured cells
using an RNA isolation kit (Qiagen,), according to the
manufacturer's protocol. M6P/IGF2R transcripts were
amplified using the primers (5'-GACAGGCTCGTTCT-
GACTTA-3') and (5'-CTTCCACTCTTATCCACAGC-3')
specific to the M6P/IGF2R. Each RT-PCR assay was per-
formed in triplicate and product levels varied by less than
3.2% for each RNA sample. Primers specific for β-actin
cDNA were added to a parallel reaction to standardize for
Effect of the ribozyme on the apoptosis and viability of cardiac myocytes Figure 7
Effect of the ribozyme on the apoptosis and viability of cardiac myocytes. Cells were infected with either Ad-GFP or Ad-GFP/
IGF2R-Rz and challenged with hypoxia (A) or TNF (B). Apoptotic cells were assayed using the Cell Death ELISA assay and cell 
viability was analyzed by MTT assay. The data are average ± SE of at least three independent experiments (*, p < 0.05 versus 
control).BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/15
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variations in PCR between samples. PCR products were
resolved on a 1.0% agarose gel, visualized under UV light
and quantitated using NIH Imager.
RPA was performed using the RPA III kit (Ambion, Austin,
TX). Briefly, total RNA was extracted from cultured cells
using a total RNA isolation reagent (TRIzol, Gibco BRL)
according to the manufacturer's protocol. The plasmid
containing the rat M6P/IGF2R gene was linearized and
used as a transcription template. Antisense RNA probes
were transcribed in vitro using [33P]-UTP, T7 polymerase
(Riboprobea System T7 kit, Promega), hybridized with
the total RNA extracted from the rat cardiomyocytes, and
digested with ribonuclease to remove non-hybridized
RNA and probe. The protected RNA·RNA was resolved on
a denaturing 5% sequence gel and subjected to autoradi-
ography. A probe targeting the GAPDH gene was used as
an internal control.
Measurement of 125I-IGF-II internalization
Cells were incubated at 37°C for 2 hrs in serum-free F-10
culture medium containing 125I-labeled IGF-II (0.5 ng/
ml) with or without excess unlabeled IGF-II (2 µg/ml).
Following the incubation, the cells were washed three
times with ice-cold PBS, and cell-associated radioactivity
was determined by a γ counter. Specific internalized 125I-
IGF-II was calculated by subtracting the count of samples
with excessive unlabeled IGF-II from that without unla-
beled IGF-II, and normalized to protein contents.
Beta-glucuronidase binding assay
Binding of β-glucuronidase was assayed as described pre-
viously [34,35]. Briefly, cells were permeabilized with
0.25% saponin in 50 mM Hepes (pH 7.0), 150 mM NaCl,
5 mM β-glycerophosphate, 0.5% human serum albumin,
and 10 mM mannose-6-phosphate (M6P) for 30 minutes
on ice. The cells were washed three times with ice-cold
PBS containing 0.05% saponin. They were incubated with
20,000 units/ml β-glucuronidase from bovine liver
(Sigma) in 50 mM Hepes (pH 7.5) containing 150 mM
NaCl, 5 mM β-glycerophosphate, 0.5% human serum
albumin, 0.5% saponin with or without 10 mM M6P
overnight on ice. Cells were washed five times with ice-
cold PBS containing 0.05% saponin and sonicated in 100
mM sodium acetate (pH 4.6). The protein concentration
of solubilized cell extract was measured and enzyme activ-
ity was assayed as follows: for each reaction 50 ul cell
extract were added to 500 ul of 100 mM sodium acetate
(pH 4.0) containing 1 mM paranitrophenyl (PNP)-β-glu-
curonide (Sigma) as substrate. After an incubation period
of 3 hours at 37°C, 500 ul 1 M Na2CO3 were added to
each reaction and the absorbance was measured at 400
nm. Experimental values were compared to a standard
curve that was constructed using 1–100 nM solutions of
PNP (Sigma) in 500 ul 100 mM sodium acetate and 500
u1 1 M Na2CO3. Specific activity was calculated as nM of
PNP produced/hour/mg of protein.
Beta-glucuronidase endocytosis assay
Beta-glucuronidase endocytosis assay was carried out as
described previously [36]. Briefly, confluent cell cultures
were washed twice with pre-warmed serum-free DMEM
followed by incubation with DMEM containing 5 mg/ml
human serum albumin and 10 mM M6P for 20 minutes.
Following incubation cells were washed 3 times with pre-
warmed DMEM. Cells were then incubated in DMEM con-
taining 5 mg/ml human serum albumin alone or 4000
units β-glucuronidase with or without 10 mM M6P for 2
hours at 37°C. Following the incubation, the cells were
washed 5 times with ice-cold PBS and subjected to
enzyme activity assay as described above.
Cell proliferation assay (MTT assay and cell counts)
Cardiac myocytes were grown in culture plates (tissue cul-
ture grade, 12 wells, flat bottom) in a final volume of 1 ml
serum-containing culture medium per well, in a humidi-
fied atmosphere (37°C and 5% C02) for 3 days. After
infection with Ad-GFP/IGF2R-Rz or Ad-GFP, cells were
incubated with or without 50 ng/ml IGF-II for 4 days. Fol-
lowing supplementation with IGF-II, 100 µl MTT labeling
reagent (Roche) were added to each well and cells were
incubated for 4 hours, followed by addition of 1 ml solu-
bilization solution into each well. The plate was placed in
an incubator at 37°C overnight. Spectrophotometrical
absorbency of the samples was measured using an UV-vis-
ible Recording Spectrophotometer with wavelength of
550–690 nm. In addition, the total number of viable cells
in each treatment was counted by trypan blue exclusion
method using a hemocytometer.
Induction and analysis of cell apoptosis
Cells were infected with Ad-GFP or Ad-GFP/IGF2R-Rz.
Seventy-two hours post infection, cells were treated with
TNF (0.1 ng/ml) for 24 hrs or subjected to hypoxia. For
induction of apoptosis by hypoxia, cell culture medium
was changed to serum-free F-10 saturated with 95% N2/
5% CO2 and cells were placed in a 37°C airtight box satu-
rated with 95% N2/5% CO2 for 24 hrs. For normoxic con-
trols, culture medium was changed to F-10/5%F BS/10%
HS and cells were placed in a 37°C/5% CO2 incubator for
24 hrs before analysis.
Apoptotic cells were identified by Hoechst staining using
the Vybrant™ Apoptosis Kit #5 (Molecular Probes) accord-
ing to the manufacturer's protocol. In addition, after
infection with Ad-GFP or Ad-GFP/IGF2R-Rz and chal-
lenge with either TNF or hypoxia, cell viability was
assessed using the MTT assay Kit (Roche Molecular Bio-
chemicals) and cell apoptosis was determined using theBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/15
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Cell Death Detection ELISA Kit assay (Roche Molecular
Biochemicals) according to the manufacturer's protocol.
Statistical analysis
Students' t-test was used to evaluate the difference
between two values. Each experiment was repeated at least
three times. Statistical significance was accepted at the
level of p < 0.05.
List of abbreviations used
Ad-GFP, adenovirus carrying GFP gene; Ad-GFP/IGF2R-
Rz, adenovirus carrying both the ribozyme against M6P/
IGF2R and the GFP gene; GFP, green fluorescent protein;
IGF-II, insulin-like growth factor II; M6P/IGF2R, mannose
6-phosphate/insulin-like growth factor II receptor; Rz,
ribozyme.
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